Stockwatch: Rates of exchange
This article was originally published in Scrip
In Malcolm Bradbury's 1980s novel Rates of Exchange the hero, Dr Petworth, finds himself in the fictional Eastern European country of Slaka where politicians, public figures and some authors find themselves acceptable one day and officially out of favor the next. Somehow, by the time Dr Petworth makes it down to breakfast each day, the locals in Slaka are already instinctively aware of who or what is now 'in', while they have already forgotten those who are out.
You may also be interested in...
Biogen’s poor third-quarter results cannot be blamed solely on the pandemic. Pipeline attrition and underperformance in most franchises pushes all the risk onto a dubious throw of the regulatory dice.
Early in 2020, company guidance was that pandemic-related effects would have dissipated in the third quarter. Issues specific to J&J and Roche leave this broad conclusion still up in the air.
Drugs that have failed in clinical studies often come back for another go, making the same mistakes for a new cohort of investors who missed the first failure. The global pandemic is also enabling this for once- or twice-failed drugs.